PAP CAR-T / Innovative Cellular Therapeutics - LARVOL DELTA

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach. (PubMed, J Immunother Cancer) - "Our study is the first to demonstrate that PAP is a specific target for CAR-T therapy in prostate cancer, both in vitro and in vivo. We developed the CoupledCAR platform technology for solid tumor CAR-T cell therapy, enabling the expansion of tumor-targeting CAR-T cells without requiring tumor antigens and thereby enhancing their functionality against solid tumors."

IO biomarker • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ACPP • PSAP

A phase I clinical trial evaluating the safety and preliminary efficacy of PAP CAR-T cells for the treatment of desmoplasia-resistant prostate cancer (SITC 2024) - P=N/A | "Patients underwent leukapheresis half a month prior to infusion, followed by lymphodepletion with cyclophosphamide 300mg/m² + fludarabine 30mg/m². Conclusions This Phase I clinical trial, which included three patients with advanced CRPC, demonstrated that PAP CAR-T cells are safe, feasible and effective in the treatment of CRPC patients. The potential impact of PAP CAR-T cell therapy on the long-term survival of CRPC patients will continue to be monitored."

CAR T-Cell Therapy • Clinical • IO biomarker • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ACPP • PSAP

SITC conference attracts worldwide attention: Clinical trial of CAR-T therapy for prostate cancer shows 80% PSA remission rate! [Google translation] (Stockstar) - P=1 | N=5 | "This is an open-label, single-arm, single-drug, single-infusion Phase I clinical trial initiated by researchers in collaboration between Stansay and Shanghai Tenth People's Hospital. Three patients received infusion treatment and completed the evaluation. According to the guidelines of the 3rd Prostate Cancer Working Group (PCWG3), two patients achieved PSA remission (Note: PSA remission refers to a decrease of more than 50% in the level of PSA, a prostate cancer-specific marker, compared with the baseline), with PSA levels decreasing by 82.70% and 83.38% respectively, and a PSA remission rate of 66.7%. In terms of side effects, two patients developed grade 1 cytokine release syndrome (CRS), and no patient experienced neurotoxicity....A total of 5 patients were enrolled in the domestic IRB clinical trial of this prostate cancer product (the other 2 were enrolled in other centers), 4 of whom achieved PSA remission, with a PSA remission rate of 80%."

P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - P1 | N=15 | "Clinical Data from one research site for GCC19CART, ICT’s lead solid tumor program, for 3rd line plus relapsed/refractory metastatic colorectal cancer (R/R mCRC) shows patients receiving a dose of 2x10^6 CAR T cells / kg demonstrating a 57% (4/7) objective response rate. Pre-Clinical Data demonstrates CoupledCAR® technology promotes efficient in vivo expansion and superior functionality of CAR-T cells in a mouse model for prostate cancer."

P1 data • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer